Journal of Toxicology / 2019 / Article / Tab 1

Research Article

A Toxicological Evaluation of Methylliberine (Dynamine®)

Table 1

Results of the initial mutation test.

Concentrations (µg/plate)Salmonella typhimurium tester strainsEscherichia coli
TA 98TA 100TA 1535TA 1537WP2uvrA
S9+S9S9+S9S9+S9S9+S9S9+S9
Mean number of revertants per plate Mutation rateMeanMRMeanMRMeanMRMeanMRMeanMRMeanMRMeanMRMeanMRMeanMRMeanMR

Untreated Control18.71.0230.71.1069.71.0097.01.068.30.9613.70.859.01.176.30.9021.01.0733.30.97
DMSO Control18.31.0028.01.0070.01.0091.31.008.71.0016.01.007.71.007.01.0019.71.0034.31.00
Ultrapure Water Control79.31.008.71.0022.31.00
Test item
500022.31.2217.30.6227.70.4021.30.238.71.007.70.485.00.658.71.2420.71.0520.00.58
160023.71.2915.70.5661.70.8858.00.649.31.0810.00.637.71.008.01.1422.01.1229.30.85
50019.31.0528.01.0070.01.0080.00.8813.71.5814.30.907.30.968.31.1917.30.8834.00.99
16018.71.0223.70.8577.31.1097.31.0710.01.1515.30.966.30.837.01.0021.01.0725.00.73
5020.01.0921.70.7763.00.9088.70.9710.31.1914.00.887.30.968.01.1418.70.9524.00.70
1619.71.0727.70.9963.00.9084.30.927.30.8514.30.906.30.8310.31.4821.01.0728.70.83
518.00.9824.00.8663.00.9083.30.9112.01.3814.30.906.30.838.71.2418.00.9228.70.83
Positive controls
NPD (4 μg/plate)778.742.47
SAZ (2 μg/plate)1546.719.501301.3150.15
9AA (50 μg/plate)396.051.65
MMS (2 μL/plate)1600.071.64
2AA (2 μg/plate)2213.379.052090.722.89162.710.17124.717.81
2AA (50 μg/plate)164.74.80

Abbreviations: MR, mutation rate; DMSO, dimethyl sulfoxide; NPD, 4-nitro-1,2-phenylenediamine; SAZ, sodium azide; 9AA, 9-aminoacridine; MMS, methyl methanesulfonate; 2AA, 2-aminoanthracene. Remarks: DMSO was applied as vehicle of the test item and the positive control substances: NPD, 9AA, and 2AA. Ultrapure water was applied as vehicle for the positive control substances: SAZ and MMS. The mutation rates of the test item, untreated control, NPD, 9AA, and 2AA are given referring to DMSO. The mutation rates of the SAZ and MMS positive controls are given referring to the ultrapure water.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.